Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, is involved in the production and sale of biochemical APIs, finished dosage forms, nuclide drugs, and health products for various therapeutic areas such as cardiovascular, antitumor, urology, orthopedics, among others.
Business Segments
The company operates through four main segments: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms, Nuclear Medicine, and Other Business.
Active Pharmaceutical Ingred...
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, is involved in the production and sale of biochemical APIs, finished dosage forms, nuclide drugs, and health products for various therapeutic areas such as cardiovascular, antitumor, urology, orthopedics, among others.
The company operates through four main segments: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms, Nuclear Medicine, and Other Business.
Active Pharmaceutical Ingredients (APIs) segment
This segment focuses on the research, development, and manufacturing of chemical raw materials used in pharmaceutical production. The company supplies its API products to both domestic and international pharmaceutical manufacturers, catering to a wide range of therapeutic areas.
Finished Dosage Forms segment
This segment includes the formulation, production, and packaging of pharmaceutical preparations like tablets, capsules, injections, and other forms. The company's finished dosage form products are distributed to hospitals, pharmacies, and healthcare providers, meeting the needs of patients across various therapeutic categories.
This segment specializes in the research, development, and production of radiopharmaceuticals for medical imaging and therapy. The company's radiopharmaceutical products are utilized in hospitals and medical institutions for diagnosing and treating diseases such as cancer and cardiovascular conditions.
This segment comprises supporting activities for its core pharmaceutical operations, including technical services, contract manufacturing, and related business activities.
The company's business strategy revolves around achieving sustainable growth and fostering innovation in the pharmaceutical sector. Key strategic priorities include expanding the product portfolio, enhancing research and development capabilities, and strengthening market presence domestically and internationally.
The company places a strong emphasis on innovation to drive long-term growth and competitiveness. Investments in research and development aim to discover and develop new drugs, enhance existing products, and apply advanced technologies in pharmaceutical manufacturing. Collaborations with academic institutions, research organizations, and industry partners support the company's R&D efforts, keeping it at the forefront of scientific and technological advancements.
Environmental protection and sustainable development are integral parts of the company's business strategy. Initiatives promoting environmental and social responsibility are integrated into its operations, focusing on reducing environmental impact, enhancing resource efficiency, and supporting community health and well-being.
The company offers a wide range of products and services across its core business segments, including APIs, finished dosage forms, radiopharmaceuticals, and technical services.
In the API segment, the company manufactures various chemical raw materials known for high purity, consistent quality, and compliance with international standards. These APIs are utilized by pharmaceutical manufacturers in producing a diverse range of therapeutic products.
The finished dosage forms segment involves formulating and producing tablets, capsules, injections, and other pharmaceutical preparations tailored to healthcare providers and patients, offering therapeutic options across multiple disease areas.
In the nuclear medicine segment, the company develops and manufactures radiopharmaceuticals for medical imaging and therapy, used in diagnosing and treating diseases like cancer and cardiovascular conditions.
Additionally, the company provides technical services, contract manufacturing, and other related activities to support its pharmaceutical operations.
The company serves various geographical markets, operating both domestically and internationally.
Customers include hospitals, pharmacies, healthcare providers, and pharmaceutical manufacturers, with the company catering to a diverse customer base to meet a wide range of healthcare needs.
Sales and marketing activities involve direct sales, distribution partnerships, and technical service agreements to promote products and services to healthcare providers, hospitals, and pharmaceutical manufacturers.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was established in 1998.
Das Analystenkursziel zeigt auf einen Blick die Mindest-, Höchst- und Durchschnittserwartung der Analysten.
